Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model
ObjectiveTo explore prognostic indicators of lung adenocarcinoma with leptomeningeal metastases (LM) and provide an updated graded prognostic assessment model integrated with molecular alterations (molGPA).MethodsA cohort of 162 patients was enrolled from 202 patients with lung adenocarcinoma and LM...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.903851/full |
| _version_ | 1828726421198995456 |
|---|---|
| author | Milan Zhang Jiayi Tong Weifeng Ma Chongliang Luo Huiqin Liu Yushu Jiang Lingzhi Qin Xiaojuan Wang Lipin Yuan Jiewen Zhang Fuhua Peng Yong Chen Wei Li Ying Jiang |
| author_facet | Milan Zhang Jiayi Tong Weifeng Ma Chongliang Luo Huiqin Liu Yushu Jiang Lingzhi Qin Xiaojuan Wang Lipin Yuan Jiewen Zhang Fuhua Peng Yong Chen Wei Li Ying Jiang |
| author_sort | Milan Zhang |
| collection | DOAJ |
| description | ObjectiveTo explore prognostic indicators of lung adenocarcinoma with leptomeningeal metastases (LM) and provide an updated graded prognostic assessment model integrated with molecular alterations (molGPA).MethodsA cohort of 162 patients was enrolled from 202 patients with lung adenocarcinoma and LM. By randomly splitting data into the training (80%) and validation (20%) sets, the Cox regression and random survival forest methods were used on the training set to identify statistically significant variables and construct a prognostic model. The C-index of the model was calculated and compared with that of previous molGPA models.ResultsThe Cox regression and random forest models both identified four variables, which included KPS, LANO neurological assessment, TKI therapy line, and controlled primary tumor, as statistically significant predictors. A novel targeted-therapy-assisted molGPA model (2022) using the above four prognostic factors was developed to predict LM of lung adenocarcinoma. The C-indices of this prognostic model in the training and validation sets were higher than those of the lung-molGPA (2017) and molGPA (2019) models.ConclusionsThe 2022 molGPA model, a substantial update of previous molGPA models with better prediction performance, may be useful in clinical decision making and stratification of future clinical trials. |
| first_indexed | 2024-04-12T13:41:58Z |
| format | Article |
| id | doaj.art-6ae5ec86489f48bdbacf6740feace3c4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T13:41:58Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6ae5ec86489f48bdbacf6740feace3c42022-12-22T03:30:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.903851903851Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA ModelMilan Zhang0Jiayi Tong1Weifeng Ma2Chongliang Luo3Huiqin Liu4Yushu Jiang5Lingzhi Qin6Xiaojuan Wang7Lipin Yuan8Jiewen Zhang9Fuhua Peng10Yong Chen11Wei Li12Ying Jiang13Department of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United StatesDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDivision of Public Health Sciences, Washington University School of Medicine in St. Louis, St Louis, MO, United StatesDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United StatesDepartment of Neurology, Henan Joint International Research Laboratory of Accurate Diagnosis, Treatment, Research and Development, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaObjectiveTo explore prognostic indicators of lung adenocarcinoma with leptomeningeal metastases (LM) and provide an updated graded prognostic assessment model integrated with molecular alterations (molGPA).MethodsA cohort of 162 patients was enrolled from 202 patients with lung adenocarcinoma and LM. By randomly splitting data into the training (80%) and validation (20%) sets, the Cox regression and random survival forest methods were used on the training set to identify statistically significant variables and construct a prognostic model. The C-index of the model was calculated and compared with that of previous molGPA models.ResultsThe Cox regression and random forest models both identified four variables, which included KPS, LANO neurological assessment, TKI therapy line, and controlled primary tumor, as statistically significant predictors. A novel targeted-therapy-assisted molGPA model (2022) using the above four prognostic factors was developed to predict LM of lung adenocarcinoma. The C-indices of this prognostic model in the training and validation sets were higher than those of the lung-molGPA (2017) and molGPA (2019) models.ConclusionsThe 2022 molGPA model, a substantial update of previous molGPA models with better prediction performance, may be useful in clinical decision making and stratification of future clinical trials.https://www.frontiersin.org/articles/10.3389/fonc.2022.903851/fullleptomeningeal metastaseslung adenocarcinomamolGPA modeloverall survivaltargeted therapy |
| spellingShingle | Milan Zhang Jiayi Tong Weifeng Ma Chongliang Luo Huiqin Liu Yushu Jiang Lingzhi Qin Xiaojuan Wang Lipin Yuan Jiewen Zhang Fuhua Peng Yong Chen Wei Li Ying Jiang Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model Frontiers in Oncology leptomeningeal metastases lung adenocarcinoma molGPA model overall survival targeted therapy |
| title | Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model |
| title_full | Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model |
| title_fullStr | Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model |
| title_full_unstemmed | Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model |
| title_short | Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model |
| title_sort | predictors of lung adenocarcinoma with leptomeningeal metastases a 2022 targeted therapy assisted molgpa model |
| topic | leptomeningeal metastases lung adenocarcinoma molGPA model overall survival targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.903851/full |
| work_keys_str_mv | AT milanzhang predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT jiayitong predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT weifengma predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT chongliangluo predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT huiqinliu predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT yushujiang predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT lingzhiqin predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT xiaojuanwang predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT lipinyuan predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT jiewenzhang predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT fuhuapeng predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT yongchen predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT weili predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel AT yingjiang predictorsoflungadenocarcinomawithleptomeningealmetastasesa2022targetedtherapyassistedmolgpamodel |